financetom
Business
financetom
/
Business
/
Bristol Myers to sell psoriasis drug at 80% discount, Bloomberg News reports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bristol Myers to sell psoriasis drug at 80% discount, Bloomberg News reports
Sep 25, 2025 4:07 AM

Sept 25 (Reuters) - Bristol Myers Squibb ( BMY ) will

sell its psoriasis drug Sotyktu directly to cash-paying patients

at a more than 80% discount to the drug's list price, Bloomberg

News reported on Thursday citing the company.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Coinbase's Long-Term Thesis Underappreciated, Oppenheimer Says
Coinbase's Long-Term Thesis Underappreciated, Oppenheimer Says
Jul 22, 2024
12:06 PM EDT, 07/22/2024 (MT Newswires) -- Coinbase Global's ( COIN ) long-term prospects are highly underappreciated amid increasing regulatory clarity, Oppenheimer said in a note. With increasing regulatory clarity, adoption and potential S&P 500 inclusion, we believe Coinbase's long-term thesis is highly underappreciated, given the massive attention on current volume and regulations, analysts Owen Lau and Guru Sidaarth said....
Procter & Gamble Facing Mixed Investor Sentiment Ahead of Q4 Results, UBS Says
Procter & Gamble Facing Mixed Investor Sentiment Ahead of Q4 Results, UBS Says
Jul 22, 2024
12:07 PM EDT, 07/22/2024 (MT Newswires) -- Procter & Gamble ( PG ) is likely to deliver fiscal Q4 earnings in-line with consensus estimates, but investor sentiment is mixed and has become more debated recently, UBS said in a note emailed Monday. Bulls argue that the company's market share performance is still strong and its organic growth will accelerate even...
Ionis Pharmaceuticals Shares Rise After Positive Results for Angelman Syndrome Drug Study
Ionis Pharmaceuticals Shares Rise After Positive Results for Angelman Syndrome Drug Study
Jul 22, 2024
12:06 PM EDT, 07/22/2024 (MT Newswires) -- Ionis Pharmaceuticals ( IONS ) said Monday that results from the multiple ascending dose part of phase 1/2 study of ION582 showed consistent clinical improvement of all functional domains in patients with Angelman syndrome. Angelman syndrome is a rare genetic disorder causing developmental delays, speech impairment, seizures and balance issues. The company said...
Canada's Trans Mountain Pipeline weighs debt deal ahead of potential sale, Bloomberg News reports
Canada's Trans Mountain Pipeline weighs debt deal ahead of potential sale, Bloomberg News reports
Jul 22, 2024
July 22 (Reuters) - Oil pipeline operator Trans Mountain plans to borrow in the bond market to refinance some of its outstanding debt before the Canadian government eventually sells it, Bloomberg News reported on Monday, citing people familiar with the matter. The company said it had C$25.3 billion ($18.4 billion) debt as of March 31, per the report. The pipeline's...
Copyright 2023-2026 - www.financetom.com All Rights Reserved